Implementation of a Transcutaneous Bilirubinometer among Newborns: A Randomized Controlled Trial
- Conditions
- hyperbilirubinemianeonatal jaundice10028920
- Registration Number
- NL-OMON37522
- Lead Sponsor
- Isala Klinieken
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 550
All newborns at the pediatric- and maternity-ward with visible jaundice.
Gestational age of 32 weeks or more.
Older than 24 hours.
younger than 8 days.
Neonatal jaundice within 24 hours or after 8 days
Hemolysis present based on maternal history (for example irregular erythrocyte antibodies)
Bilirubin encephalopathy
Newborns during/after phototherapy
Large congenital anomaly at forehead/sternum
Serum bilirubin-value is already known before admission to the pediatric ward;those newborns are to be admitted because the serum bilirubin-level has reached the phototherapy or exchange transfusion limit.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Primairy outcome variable: the number of blood tests for bilirubin measurement<br /><br>(Before the potential start of phototherapy).</p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary outcome: Phototherapy duration in hours, Number of serum<br /><br>bilirubin-values above the 'exchange transfusion limit', Highest measured serum<br /><br>bilirubin-value, Cost-effectiveness (blood test, use bilirubinometer, costs<br /><br>admittance), Number of patients having kernicterus.</p><br>